NASDAQ:ARVN
Arvinas, Inc.
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
www.arvinas.comipo date
Sep 27, 2018
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of...Show More
Earnings
Earnings Release in 9 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus